Effective at the opening, Monday, Oct. 5, 2026, the shares of Appili Therapeutics Inc. will commence trading on the NEX.

The company will delist from trading on the Toronto Stock Exchange effective at the close on Oct. 2, 2026. The company no longer meets Toronto Stock Exchange minimum listing requirements and also does not meet the requirements of a TSX Venture Exchange Tier 2 company.

As of Monday, Oct. 5, 2026, the company is subject to restrictions on share issuances and certain types of payments as set out in the NEX policies.

The symbol extension differentiates NEX symbols from Tier 1 or Tier 2 symbols within the TSX Venture Exchange market. The company is classified as a research and development in the physical, engineering and life sciences issuer (NAICS No. 541710). For further information, please refer to the company's continuous disclosure information available on SEDAR+.

Corporate jurisdiction:  Ontario

Capitalization:  unlimited Class A common shares with no par value, of which 132,366,120 Class A common shares are issued and outstanding

Escrowed shares:  nil Class A common shares

Transfer agent:  Computershare Investor Services Inc.

Trading symbol:  APLI.H

Cusip No.:  03783R 10 7